The global demand for Aflibercept Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022 - 2028. Regarding volume, the market was calculated XX Kilo Tons in 2021 and forecast to touch XX Kilo Tons by 2028 with a CAGR of XX% during 2022-2028.
Aflibercept is a medication prescribed to treat wet maculat degeneration, metastatic colorectal cancer, visual impairment due to diabetic macular oedema, and diabetic retinopathy. It is injected into the eye to slow down vision loss. Aflibercept works by blocking the leaking and growth of fluid from abnormal blood vessels in the back of the eye. It is traded under the brand names Eylea and Zaltrap.
Market Dynamics
Growing cases of wet maculat degeneration, metastatic colorectal cancer, visual impairment due to diabetic macular oedema, and diabetic retinopathy will lead to an increased sale of aflibercept. Expanding geriatric population worldwide is predicted to favor aflibercept demand as this population is more prone to cause eye diseases. The number of persons above 65 years is projected to double to 1.5 billion in 2050. Colorectal cancer (CRC) is the second leading cause of cancer death in the US. Globally, there were over 1.8 million new cases in 2018. The prevalence of visual impairment among the aging population ranges from 22% to 35%. Ongoing clinical trials and growing approvals for a new treatment are expected to create new market opportunities. However, the presence of other alternative medications and trade barriers may hamper market growth during the forecast period.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of aflibercept. The growth and trends of Aflibercept Industry provide a holistic approach to this study.
Market Segmentation
This section of the aflibercept market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- Prefilled Syring Package
- Vial Package
By Application
- Wet Macular Degeneration
- Metastatic Colorectal Cancer
- Diabetic Macular Oedema
- Diabetic Retinopathy
- Others
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Aflibercept market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Aflibercept Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the aflibercept market include Bayer, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.